Ado-trastuzumab emtansine - Biologic Drug Details

Summary for ado-trastuzumab emtansine

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for ado-trastuzumab emtansine

Recent Clinical Trials for ado-trastuzumab emtansine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of Chicago	PHASE2
Tianjin Medical University Cancer Institute and Hospital	PHASE2
Zhenzhen Liu	NA

See all ado-trastuzumab emtansine clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ado-trastuzumab emtansine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ado-trastuzumab emtansine Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	KADCYLA	ado-trastuzumab emtansine	For Injection	125427	11,406,715	2036-05-27	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	KADCYLA	ado-trastuzumab emtansine	For Injection	125427	7,097,840	2021-03-16	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	KADCYLA	ado-trastuzumab emtansine	For Injection	125427	8,337,856	2027-12-03	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ado-trastuzumab emtansine Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	KADCYLA	ado-trastuzumab emtansine	For Injection	125427	10,005,783	2037-01-05	Patent claims search
Genentech, Inc.	KADCYLA	ado-trastuzumab emtansine	For Injection	125427	10,022,451	2035-05-11	Patent claims search
Genentech, Inc.	KADCYLA	ado-trastuzumab emtansine	For Injection	125427	10,265,291	2037-02-13	Patent claims search

International Patents for ado-trastuzumab emtansine

Country	Patent Number	Estimated Expiration
Russian Federation	2430739
Hong Kong	1153151
China	1387444

Supplementary Protection Certificates for ado-trastuzumab emtansine

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
300580	Netherlands		PRODUCT NAME: PERTUZUMAB; REGISTRATION NO/DATE: EU/1/13/813/001 20130304
C01189641/01	Switzerland		PRODUCT NAME: PERTUZUMAB; REG. NO/DATE: SWISSMEDIC 62510 20120813
CA 2013 00013	Denmark

Summary

Last updated: February 14, 2026

Ado-trastuzumab emtansine (Kadcyla, Roche) is a targeted antibody-drug conjugate (ADC) approved for HER2-positive breast cancer. Its market growth hinges on evolving treatment landscapes, clinical trial results, regulatory approvals, and competitive dynamics. Revenue forecasts project steady growth through the next five years, driven by expanding indications and increasing adoption in early-line settings. However, competition from biosimilars, alternative HER2-targeted therapies, and pricing pressures may temper expansion.

---

What Are the Current Market Dynamics for Ado-Trastuzumab Emtansine?

Market Size and Growth Trends

In 2022, global sales of Kadcyla approached $2.2 billion, representing approximately 18% annual growth since 2018, when sales neared $1 billion. Growth is primarily driven by increased adoption in advanced breast cancer and emerging approvals for adjuvant and early-stage settings.

Indications and Usage

Initially approved in 2013 for metastatic HER2-positive breast cancer after trastuzumab and chemotherapy. FDA expanded indication in 2019 to include adjuvant therapy for HER2-positive early breast cancer, further broadening its patient pool.

Competitive Landscape

The ADC segment for HER2-positive breast cancer includes trastuzumab deruxtecan (Enhertu, Daiichi Sankyo) and trastuzumab duocarmazine (trastuzumab-VCM, clinical stage). Biosimilars to trastuzumab (Herceptin) launched in 2018, exerting pricing pressure on combination regimens.

Pricing and Reimbursement Trends

Average wholesale prices (AWP) for Kadcyla hover around $9,500 per dose, with reimbursement and utilization heavily influenced by payer policies and regional differences. Value-based pricing models are emerging, especially in markets with cost-effectiveness assessments.

Regulatory and Policy Factors

The approval of Kadcyla for early-stage breast cancer by the FDA aligns with a broader shift toward personalized oncology, influencing prescribing patterns. Reimbursement remains consistent in major markets, though cost-containment measures could impact future access.

---

What Are the Financial Trajectories and Forecasts?

Revenue Projections

Year	Estimated Global Sales	Source/Assumptions
2022	$2.2 billion	Based on IQVIA data
2023	$2.4 billion	9% growth, reflecting expanded indications
2024	$2.6 billion	Market penetration in adjuvant settings
2025	$2.8 billion	Increasing adoption in early-stage therapy
2026	$3.0 billion	Continued growth, market maturation

Revenue Drivers

• Expanded use in adjuvant and earlier-line therapies.
• Increased testing and patient identification.
• Enhanced payer coverage and acceptance.
• Entry into new geographic markets.

Risks and Challenges

• Competitive pressure from ADCs like Enhertu, which reports revenues exceeding $2 billion in 2022.
• Biosimilar trastuzumab price erosion, reducing combination drug price points.
• Trial outcomes questioning the incremental benefit in certain populations.
• Manufacturing complexity and supply chain disruptions.

Profitability Outlook

Margins are influenced by manufacturing costs, pricing pressures, and reimbursement landscapes. Roche reports gross margins around 70% for Kadcyla, with potential erosion in highly regulated markets.

---

How Do Competitive and Scientific Factors Affect the Financial Outlook?

Advances in HER2 Targeting

Trastuzumab deruxtecan demonstrates higher response rates in metastatic settings, challenging Kadcyla’s market share. Clinical trials comparing ADCs seek to establish best-in-class status and could reshape revenue streams.

Clinical Trial Data

The DESTINY-Breast03 trial showed trastuzumab deruxtecan’s superior progression-free survival versus T-DM1, leading to increased adoption. Expected results from ongoing studies may influence future sales trajectories.

Regulatory and Reimbursement Policies

Regional approvals for adjuvant indications vary. In Europe, NICE and similar bodies enforce pricing and access restrictions, affecting revenue potential.

---

Key Takeaways

• Ado-trastuzumab emtansine commands a significant market share in HER2-positive breast cancer, driven by its targeted mechanism and expanded indications.
• Market growth will depend on clinical trial results, competitive ADC innovations, regulatory approvals, and pricing strategies.
• Revenue is expected to grow approximately 9% annually through 2026 but faces risks from biosimilar and rival ADC competition.
• The global launch of new formulations and combinations may diversify revenue streams, contingent on clinical proof and payer acceptance.
• Roche’s strategic focus on early-line and adjuvant therapy indications will be pivotal in maintaining revenue momentum.

---

FAQs

1. What is the primary mechanism of action for Ado-Trastuzumab Emtansine?
   It combines trastuzumab, a HER2-targeting antibody, with emtansine, a cytotoxic agent, delivering targeted chemotherapy to HER2-positive tumor cells.

2. How does the current competition affect Ado-Trastuzumab Emtansine’s market share?
   Enhertu’s superior efficacy in certain metastatic settings and biosimilar pressures on trastuzumab may reduce Kadcyla’s market share over time.

3. What are the main factors influencing the pricing of Kadcyla?
   Pricing is impacted by regional healthcare policies, cost-effectiveness evaluations, competing therapies, and reimbursement models.

4. Are there upcoming regulatory decisions that could impact global sales?
   Upcoming decisions include approvals for earlier-line or adjuvant indications in various jurisdictions, potentially expanding market size.

5. What is Roche’s strategy to sustain Kadcyla’s growth?
   Focusing on indications expansion, exploring combination therapies, and engaging in clinical trials to establish longer-term efficacy and safety.

---

Citations

[1] IQVIA. "Global Oncology Therapeutics Market Data," 2022.
[2] Roche. "Kadcyla Product Information," 2022.
[3] U.S. Food and Drug Administration. "FDA Approvals and Labeling," 2019.
[4] Daiichi Sankyo. "Enhertu Sales Data," 2022.
[5] NICE. "Guidelines on HER2-Targeted Therapies," 2023.